Table 2.

Primary and secondary outcome measures of survival in intention-to-treat population

Outcome	Cilengitide 240 mg/m2 n = 35	Cilengitide 400 mg/m2 n = 35	Cilengitide 600 mg/m2 n = 36	Docetaxel 75 mg/m2 n = 34
Median PFS, days [95 % CI]	54 [43–64]	63 [53–66]	63 [42–67]	67 [61–123]
Median OS, days [95 % CI]	173 [81–197]	117 [92–209]	181 [90–326]	194 [135–298]
1-year survival rate, % [95 % CI]	13 [1.2–24.4]	13 [0.4–25.5]	29 [12.3–46.5]	27 [10.4–43.4]

CI, confidence interval; OS, overall survival; PFS, progression-free survival